ALK benefits from Mylan's Epipen woes

Mylan's present difficulties in delivering its adrenalin pen, Epipen, in Britain are benefiting the Danish, allergy-focused pharmaceutical company ALK, which has increased production of its own version of the product in order to meet increasing demand.

ALK has increased production of its adrenalin pen, Jext.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles